Publication: What pulmonologists think about the asthma-COPD overlap syndrome.
dc.contributor.author | Miravitlles, Marc | |
dc.contributor.author | Alcázar, Bernardino | |
dc.contributor.author | Alvarez, Francisco Javier | |
dc.contributor.author | Bazús, Teresa | |
dc.contributor.author | Calle, Myriam | |
dc.contributor.author | Casanova, Ciro | |
dc.contributor.author | Cisneros, Carolina | |
dc.contributor.author | de-Torres, Juan P | |
dc.contributor.author | Entrenas, Luis M | |
dc.contributor.author | Esteban, Cristóbal | |
dc.contributor.author | García-Sidro, Patricia | |
dc.contributor.author | Cosio, Borja G | |
dc.contributor.author | Huerta, Arturo | |
dc.contributor.author | Iriberri, Milagros | |
dc.contributor.author | Izquierdo, José Luis | |
dc.contributor.author | López-Viña, Antolín | |
dc.contributor.author | López-Campos, José Luis | |
dc.contributor.author | Martínez-Moragón, Eva | |
dc.contributor.author | Pérez de Llano, Luis | |
dc.contributor.author | Perpiñá, Miguel | |
dc.contributor.author | Ros, José Antonio | |
dc.contributor.author | Serrano, José | |
dc.contributor.author | Soler-Cataluña, Juan José | |
dc.contributor.author | Torrego, Alfons | |
dc.contributor.author | Urrutia, Isabel | |
dc.contributor.author | Plaza, Vicente | |
dc.contributor.authoraffiliation | [Miravitlles,M] Pneumology Department, Hospital Universitari Vall d´Hebron, Barcelona, Spain. [Miravitlles,M; López-Campos,L] CIBER de Enfermedades Respiratorias (CIBERES) Madrid, Spain. [Alcázar,B] Respiratory Department, Hospital de Alta Resolución de Loja, Granada, Spain. [Alvarez,FJ; López-Campos,L] Medical-Surgical Unit of Respiratory Diseases, Virgen del Rocio University Hospital, Biomedicine Institute of Seville (IbiS), Seville, Spain. [Bazús,T] Department of Pneumology, Hospital Universitario Central de Asturias, Ovido, Spain. [Calle,M] Department of Pneumology, Hospital Clínico San Carlos, Madrid, Spain. [Casanova,C] Department of Pneumology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain. [Cisneros,C] Department of Pneumology, Hospital Universitario de La Princesa/Instituto de Investigación Sanitaria (IIS-IP), Madrid, Spain. [De Torres,JP] Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain. [Entrenas,LM] Department of Pneumology, Hospital Universitario Reina Sofía, Córdoba, Spain. [Esteban,C; Urrutia,I] Department of Pneumology, Hospital Galdakao-Usansolo, Galdakao, Spain. [García-Sidro,P] Department of Pneumology, Hospital Universitario de La Plana, Vila-Real, Spain. [Cosio,BC] Department of Pneumology, Hospital Universitario Son Espases IdISPa, Palma de Mallorca, Spain. [Huerta,A] Sección Urgencias Medicina - Neumología, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Spain. [Iriberri,M] Department of Pneumology, Hospital Universitario de Cruces, Bilbao, Spain. [Izquierdo,JL] Department of Pneumology, Hospital Universitario de Guadalajara, Guadalajara, Spain. [López-Viña,A] Department of Pneumology, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain. [Martínez-Moragón,E] Department of Pneumology, Hospital Universitario Dr. Peset, Valencia, Spain. [Pérez de Llano,L] Department of Pneumology, Hospital Universitario Lucus Augusti, Lugo, Spain. [Perpiñá,M] Department of Pneumology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. [Ros,JA] Department of Pneumology, Hospital Clínico Universitario Virgen de la Arrinxaca, Murcia, Spain. [Serrano,J] Department of Pneumology, Hospital Comarcal de Inca, Inca, Spain. [Soler-Cataluña,JJ] Department of Pneumology, Hospital Arnau de Vilanova-Liria, Valencia, Spain. [Torrejo,A; Plaza,V] Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. | es |
dc.contributor.funder | Marc Miravitlles has received speaker fees from Almirall, Boehringer Ingelheim, Pfizer, AstraZeneca, Chiesi, Esteve, GlaxoSmithKline, Menarini, Grifols, and Novartis, and consulting fees from Almirall, Boehringer Ingelheim, Cipla, Pfizer, GlaxoSmithKline, Gebro Pharma, CLS Behring, MediImmune, Takeda, Teva, Novartis, and Grifols. Bernardino Alcázar reports personal fees from Novartis AG, Boehringer Ingelheim, GSK, Almirall, AstraZeneca, and grants and personal fees from Menarini. Teresa Bazús has received honoraria or funding for attending scientific meetings from GSK, Chiesi, and Teva. Ciro Casanova has received speaker fees from AstraZeneca, GSK, Novartis, and Almirall y Gebro Pharma and consulting fees from Almirall, Novartis, and GSK. Carolina Cisneros has received speaker or consulting fees from AstraZeneca, GSK, Boehringer Ingelheim, Novartis, Takeda, Vifor Pharma, Chiesi, Orion, and Mundipharma. Luis M Entrenas has in the last 3 years received honoraria for speaking at sponsored meetings from Alter, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Menarini, MSD, Mundipharma, Novartis, Pfizer, and Teva, as a consultant for Chiesi, Mundipharma, and Novartis, and has received funding/grant support for research projects from not-for-profit foundations, as well as Novartis. Patricia García-Sidro has received fees for scientific meetings, scientific advice, and participating in clinical studies or writing for publications from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, Gebro, GlaxoSmithKline, Menarini, MSD, Mundipharma, Novartis, Pfizer, Rovi, Takeda-Nycomed, and Teva. Borja G Cosio has in the last 3 years received honoraria for speaking at sponsored meetings from Chiesi, GSK, Boehringer Ingelheim, Novartis, and Pfizer, consultant fees from Pfizer, Chiesi, and GSK, travel grants from Boehringer Ingelheim, Novartis, and Chiesi, and received unrestricted funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Boehringer Ingelheim, Chiesi, and Menarini. Arturo Huerta has received personal fees from GSK, Novartis, Takeda, Menarini, and Boehringer Ingelheim. José Luis Izquierdo reports personal fees for consulting and lectures from Almirall, AstraZeneca, Bayer, Boehringer Ingelheim, Takeda-Nycomed, Pfizer, and Menarini. Antolin López-Viña has in the last 3 years received honoraria for speaking at sponsored meetings from Chiesi, GSK, Boehringer Ingelheim, Novartis, and Pfizer, as a consultant for Pfizer, Boehringer Ingelheim, and Novartis, has received assistance to meet travel costs from Boehringer Ingelheim, Novartis, Teva, and Chiesi, and has received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Chiesi and Menarini. Eva Martínez-Moragón has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Teva, and Pfizer. Luis Pérez de Llano has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Menarini, Chiesi, GlaxoSmithKline, Teva, Almirall, Mundipharma, Esteve, Novartis, and Pfizer, as a consultant for Mundipharma, Pfizer, Ferrer, and Novartis, has received assistance to meet travel costs from GSK and Novartis, and has received funding/grant support for research projects from SEPAR and SERGAS. Juan José Soler-Cataluña has received speaker fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Merck, Menarini, Sharp & Dohme, Novartis, Takeda, and Pfizer, and consulting fees from Boehringer Ingelheim, GSK, AstraZeneca, Ferrer, Novartis, Almirall, Merck, Sharp & Dohme, and Takeda. Vicente Plaza has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, and Pfizer, as a consultant for Mundipharma, Orion and Teva, received assistance to meet travel costs from Boehringer Ingelheim and Chiesi, and received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Chiesi, Menarini, and Merck. The authors report no other conflicts of interest in this work. | |
dc.date.accessioned | 2016-08-10T07:27:44Z | |
dc.date.available | 2016-08-10T07:27:44Z | |
dc.date.issued | 2015-07-15 | |
dc.description | Journal Article; Research Support, Non-U.S. Gov't; | es |
dc.description.abstract | BACKGROUND Some patients with COPD may share characteristics of asthma; this is the so-called asthma-COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. MATERIALS AND METHODS We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. RESULTS A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity <0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. CONCLUSION Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids. | es |
dc.description.version | Yes | es |
dc.identifier.citation | Miravitlles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, et al. What pulmonologists think about the asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2015; 10:1321-30 | es |
dc.identifier.doi | 10.2147/COPD.S88667 | |
dc.identifier.essn | 1178-2005 | |
dc.identifier.issn | 1176-9106 | |
dc.identifier.pmc | PMC4507793 | |
dc.identifier.pmid | 26270415 | |
dc.identifier.uri | http://hdl.handle.net/10668/2348 | |
dc.journal.title | International Journal of Chronic Obstructive Pulmonary Disease | |
dc.language.iso | en | |
dc.publisher | Dove Medical Press | es |
dc.relation.publisherversion | https://www.dovepress.com/what-pulmonologists-think-about-the-asthmandashcopd-overlap-syndrome-peer-reviewed-article-COPD | es |
dc.rights.accessRights | open access | |
dc.subject | Asthma | es |
dc.subject | COPD | es |
dc.subject | Survey | es |
dc.subject | ACOS | es |
dc.subject | Guidelines | es |
dc.subject | Asma | es |
dc.subject | Antiasmáticos | es |
dc.subject | Broncodilatadores | es |
dc.subject | Consenso | es |
dc.subject | Corticoesteroides | es |
dc.subject | Enfermedad pulmonar obstructiva crónica | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Adrenergic Agents::Adrenergic Agonists::Adrenergic beta-Agonists::Adrenergic beta-2 Receptor Agonists | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Respiratory System Agents::Anti-Asthmatic Agents | es |
dc.subject.mesh | Medical Subject Headings::Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Asthma | es |
dc.subject.mesh | Medical Subject Headings::Psychiatry and Psychology::Behavior and Behavior Mechanisms::Attitude::Attitude of Health Personnel | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Respiratory System Agents::Anti-Asthmatic Agents::Bronchodilator Agents | es |
dc.subject.mesh | Medical Subject Headings::Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus | es |
dc.subject.mesh | Medical Subject Headings::Check Tags::Female | es |
dc.subject.mesh | Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Delivery of Health Care::Attitude to Health::Health Knowledge, Attitudes, Practice | es |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans | es |
dc.subject.mesh | Medical Subject Headings::Check Tags::Male | es |
dc.subject.mesh | Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Research Design::Sensitivity and Specificity::Predictive Value of Tests | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis | es |
dc.subject.mesh | Medical Subject Headings::Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Pulmonary Disease, Chronic Obstructive | es |
dc.subject.mesh | Medical Subject Headings::Disciplines and Occupations::Health Occupations::Medicine::Internal Medicine::Pulmonary Medicine | es |
dc.subject.mesh | Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Causality::Risk Factors | es |
dc.subject.mesh | Medical Subject Headings::Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking | es |
dc.subject.mesh | Medical Subject Headings::Geographicals::Geographic Locations::Europe::Spain | es |
dc.subject.mesh | Medical Subject Headings::Disciplines and Occupations::Health Occupations::Specialization | es |
dc.subject.mesh | Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Data Collection::Questionnaires | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones | es |
dc.subject.mesh | Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Aged | es |
dc.title | What pulmonologists think about the asthma-COPD overlap syndrome. | es |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Miravitlles_What.pdf
- Size:
- 374.74 KB
- Format:
- Adobe Portable Document Format
- Description:
- Articulo publicado